Vivos Therapeutics, Inc. (VVOS)

Market Cap	26.42M
Revenue (ttm)	14.39M
Net Income (ttm)	-14.32M
Shares Out	7.50M
EPS (ttm)	-1.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,418,817
Open	3.370
Previous Close	3.400
Day's Range	3.170 - 3.700
52-Week Range	1.980 - 7.950
Beta	6.99
Analysts	Strong Buy
Price Target	6.25 (+77.56%)
Earnings Date	Nov 13, 2025

About VVOS

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related t...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 109
• Stock Exchange: NASDAQ
• Ticker Symbol: VVOS
• Website: https://www.vivos.com

Financial Performance

In 2024, Vivos Therapeutics's revenue was $15.03 million, an increase of 8.91% compared to the previous year's $13.80 million. Losses were -$11.14 million, -18.02% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for VVOS stock is "Strong Buy." The 12-month stock price target is $6.25, which is an increase of 77.56% from the latest price.

Price Target

$6.25

(77.56% upside)

Analyst Consensus: Strong Buy